Article published Sep 28, 2026. Prices below use latest available snapshots.
MDT Price Structure
Loading timeframes…
$MDT is holding up: roughly flat since August 28 (down 1.9%), up 10.6% since June 29 and 0.7% above its 200-day average, down 4.8% over the past year. At the 2026-09-28 settled close, MDT $89.50 was -2.3% versus its 20-day average and -1.9% over 30 days. The newest verified quarter ends 2026-07-31 (filed 2026-09-03); revenue was $9.76B. Against 2025-07-25 revenue of $8.58B, that is +13.7% year over year. The one-year return is -4.8%, 20.1 points behind the benchmark; this remains a repair rather than an established long trend. The standing call is 🟡 Wait for the post-earnings high to be retaken. Entry $92–$95 on a close above $94.17 · stop $85 · first target $100 · low conviction.
Quick Snapshot (as of 2026-09-28)
| Question | Answer |
|---|---|
| The call | 🟡 Wait for the post-earnings high to be retaken. Entry $92–$95 on a close above $94.17 · stop $85 · first target $100 · low conviction |
| What is Medtronic? | A diversified medical-device maker — cardiovascular, neuroscience, surgical and diabetes products — selling mostly to hospitals. |
| Why look now? | Prior case (2026-09-23): Fiscal Q1 FY2027 (reported 2026-09-01) beat and raised full-year guidance; the stock has spent three weeks giving that pop back. |
| What is the proof? | Latest verified period ended 2026-07-31, filed 2026-09-03: revenue $9.76B. Prior case: The September 1 release and its coverage: a broad-based beat and a raised fiscal 2027 outlook, with the shares jumping on the print (desk event record and the September 6 news pull). |
| What is the objection? | The one-year return is -4.8%, 20.1 points behind the benchmark; this remains a repair rather than an established long trend. |
| Stock setup | The shorter trend has repaired, but the trailing year still trails; -2.3% versus the 20-day, +0.7% versus the 200-day, RSI 44.8. |
Action Matrix (reviewed 2026-09-28; levels are standing conditions)
| Signal | Condition | Level | Why |
|---|---|---|---|
| 🟡 Wait | Price holding the 200-day | 200-day, $89.09 on 2026-09-23 | The line is being tested, not yet passed or failed |
| 🟢 Buy | A close above the September 4 post-earnings close | $94.17 | A structural high, not a moving average; retaking it says the earnings pop was not a one-off |
| 🔴 Out | Two closes below the 200-day | below $89 | Would reopen the pattern that ran from February through May |
| 🟠 Target | First target | $100 | A round planning level beneath the 52-week high |
| 🔴 Thesis breaks | A guidance cut or a close below the May 29 low | $73.81 | Would say the September beat did not change the business |
The Story Right Now (as of 2026-09-28)
$MDT is holding up: roughly flat since August 28 (down 1.9%), up 10.6% since June 29 and 0.7% above its 200-day average, down 4.8% over the past year.
Data as of 2026-09-28 close: MDT $89.5, RSI 44.8, weak-down, -2.3% vs SMA20, +0.7% vs SMA200, 7D -2.5%, 30D -1.9%, 1Y -4.8%, -15.8% from the 52-week high.
Business and mechanism. A diversified medical-device maker — cardiovascular, neuroscience, surgical and diabetes products — selling mostly to hospitals.
Prior case (2026-09-23). Fiscal Q1 FY2027 (reported 2026-09-01) beat and raised full-year guidance; the stock has spent three weeks giving that pop back.
Prior proof (2026-09-23). The September 1 release and its coverage: a broad-based beat and a raised fiscal 2027 outlook, with the shares jumping on the print (desk event record and the September 6 news pull).
The countercase. The one-year return is -4.8%, 20.1 points behind the benchmark; this remains a repair rather than an established long trend.
Newest statement check. The newest verified quarter ends 2026-07-31 (filed 2026-09-03); revenue was $9.76B. Against 2025-07-25 revenue of $8.58B, that is +13.7% year over year.
News and attention check. The news search for the latest move failed; the last completed search was on 2026-09-06. No company event for MDT was recorded between September 24 and 28.
The call: 🟡 Wait for the post-earnings high to be retaken. Entry $92–$95 on a close above $94.17 · stop $85 · first target $100 · low conviction.
Extended analysis
Price Data (live — latest settled close)
A live table: every cell shows the latest settled close, named in the first row. Dated readings live in the Research Log.
| Metric | Value |
|---|---|
| As of (settled close) | 2026-10-16 |
| Price ($) | 94.75 |
| RSI (14) | 64.1 |
| 20-day average ($) | 89.54 |
| vs 20-day (%) | 5.8 |
| 50-day average ($) | 90.89 |
| vs 50-day (%) | 4.2 |
| 200-day average ($) | 88.3 |
| vs 200-day (%) | 7.3 |
| 1D (%) | -0.73 |
| 7D (%) | 7.09 |
| 30D (%) | 2.32 |
| 3M (%) | 13.88 |
| 1Y (%) | -0.31 |
| 1Y vs benchmark (points) | -15.84 |
| From 52-week high (%) | -10.89 |
Financial Proof
Filed-period check (as of 2026-09-28): The newest verified quarter ended 2026-07-31 and was filed 2026-09-03. Revenue was $9.76B. Source: SEC key financials and the filing. Dated historical tables below retain their own period basis.
The recent filed revenue series shows the direction of the business; missing cells are left unavailable.
| Period end | Revenue | Filing date |
|---|---|---|
| 2024-01-26 | $8.09B | 2025-02-25 |
| 2024-07-26 | $7.92B | 2025-08-26 |
| 2024-10-25 | $8.40B | 2025-11-25 |
| 2025-01-24 | $8.29B | 2026-02-24 |
| 2025-07-25 | $8.58B | 2026-09-03 |
| 2025-10-24 | $8.96B | 2025-11-25 |
| 2026-01-23 | $9.02B | 2026-02-24 |
| 2026-07-31 | $9.76B | 2026-09-03 |
Research Log
| Date | Update |
|---|---|
| 2026-04-10 | Created deep dive — MDT stabilizing at $87.35, RSI 44.4. |
| 2026-05-29 | MDT $73.81, RSI 30.5, strong-down; 30D -8.84%, 3M -24.15%, -30.58% from 52wkHi. No new fundamentals re-researched. |
| 2026-06-16 | MDT $81.32, RSI 57, recovering; 7D -2.18%, 30D +5.17%, 3M -7.3%; -23.52% from 52wkHi; +3.5% above SMA20 ($78.54). RSI recovery from oversold 30.5 → 57 is significant. Price has reclaimed SMA20. No new fundamentals re-researched. |
| 2026-07-11 | MDT $83.87, RSI 60.6, weak-up; 7D +2.16%, 30D +5.35%, 3M -3.83%; -21.12% from 52wkHi; +4.1% above SMA20 ($80.54). No new fundamentals re-researched. |
| 2026-07-17 | MDT $83.20, RSI 56.0, weak-up; 7D -0.8%, 30D +5.81%, 3M -1.23%; -21.75% from 52wkHi; +2.5% above SMA20 ($81.21). No new fundamentals re-researched. |
| 2026-07-25 | MDT $83.21, RSI 55.7, weak-up; 7D +0.01%, 30D +4.79%, 3M +0.78% (flipped positive); -22.87% from 52wkHi; +1.4% above SMA20 ($82.03). No new fundamentals re-researched. |
| 2026-07-28 | MDT $86.88, RSI 64.6, weak-up; 7D +5.5%, 30D +7.35%, 3M +10.45%; -18.29% from 52wkHi (best mark yet); +5.5% above SMA20, +8.9% above SMA50. No new fundamentals re-researched. |
| 2026-07-31 | MDT $85.39, RSI 58.3, weak-up; 7D +2.62%; 30D +7.82%; 3M +7.71%; -19.69% from 52wk high. No new fundamentals re-researched. |
| 2026-08-08 | MDT $87.16, RSI 62.3, weak-up; 7D +2.07%; 30D +6.28%; 3M +15.49%; -19.13% from 52wk high. No new fundamentals re-researched. |
| 2026-08-14 | MDT $91.27, RSI 71.4, up; 7D +4.72%; 30D +13.42%; 3M +20.94%; -14.81% from 52wk high. No new fundamentals re-researched. |
| 2026-08-22 | MDT $93.35, RSI 68.4, up; 7D +2.30%; 30D +13.99%; 3M +18.77%; -12.21% from 52wk high. 1Y +2.47%, vs SMA200 +4.00%. No new fundamentals re-researched. |
| 2026-08-28 | MDT $91.23, RSI 57, up; 7D -2.29%; 30D +4.22%; 3M +23.60%; -14.20% from 52wk high. 1Y -0.79%, vs SMA200 +1.6%. No new fundamentals re-researched. |
| 2026-09-04 | MDT $94.17, RSI 64.5, up; 7D +3.25%; 30D +9.51%; 3M +15.31%; -11.44% from 52wk high. 1Y +1.42%, vs SMA200 +5.00%. Reported fiscal Q1 FY2027 results 2026-09-01: beat across the board and raised full-year guidance; coverage in the pull says shares surged nearly 9% on the print. Source: the September 1 MDT earnings event note; news pull dated September 5. |
| 2026-09-11 | MDT $90.96, RSI 51.6, up; 7D -3.41%; 30D +0.22%; 3M +13.42%; -14.45% from 52wk high. 1Y -3.49% (turned negative from +1.42%), vs SMA200 +1.60% — still above the 200-day but the trailing year flipped negative; alpha1y -19.7%. Stock-events checked, none new. News not pulled for this move (last fetched 2026-09-06, before this window). No new fundamentals filed since 09-04. |
| 2026-09-18 | MDT $92.13, RSI 53.3, up; 1D -0.69%; 7D +1.29%; 30D -2.12%; 3M +16.12%; -13.35% from 52wk high. 1Y -3.62% with alpha1y -18.63, but price is +3.2% above the 200-day and +3.9% above the 50-day — a repair holding, not an intact multi-year uptrend. The prior cycle's held-position and stop-level commentary was removed from this log: recommendation surfaces are book-blind. Stock-events checked: no MDT row dated 2026-09-12 to 2026-09-18. News not pulled for this move — receipt last written 2026-09-06. No newly filed period on disk: the newest filed quarter ends 2026-04-24, so the fiscal Q1 FY2027 results released 2026-09-01 are not yet in the filing cache. |
| 2026-09-23 | MDT $89.30, RSI 42.6, strong-up; 1D -1.62%; 7D -3.56%; 30D -3.88%; 3M +11.44%; -16.02% from 52wk high. 1Y -5.96% with a one-year excess return of -21.73 points; price +0.2% above the 200-day and +0.1% above the 50-day — the repair is on its 200-day for the first time. Top rewritten with a call keyed to a structural level (the 2026-09-04 post-earnings close, $94.17) rather than a moving average. Stock-events checked: no MDT row dated 2026-09-19 to 2026-09-23. News not pulled for this move — receipt last written 2026-09-06. No newly filed period on disk: newest filed period still ends 2026-04-24 (10-K filed 2026-06-18); fiscal Q1 FY2027, reported 2026-09-01, is not in the filing cache. |
| 2026-09-28 | MDT $89.50, RSI 44.8, -2.3% vs SMA20, 30D -1.9%. The shorter trend has repaired, but the trailing year still trails; The newest verified quarter ends 2026-07-31 (filed 2026-09-03); revenue was $9.76B. Against 2025-07-25 revenue of $8.58B, that is +13.7% year over year. The news search for the latest move failed; the last completed search was on 2026-09-06. No company event for MDT was recorded between September 24 and 28. |
Sources
- Earnings event note: 2026-09-01-mdt-earnings.
- News receipt: latest (fetched 2026-09-06, before this move).
- Scheduled-event check:
research/stock-events/— no MDT row dated 2026-09-12 to 2026-09-23. - Prior-cycle history: this file's dated update log.
2026-09-28 refresh receipts
2026-09-28 settled-close receipt: *, MDT row dated 2026-09-28; tape values above are bound to the current summary fields.
2026-09-28 financial-period check: income-statements and key-financials; newest verified 2026-07-31 period, filed 2026-09-03 (SEC XBRL direct quarter).
2026-09-28 news receipt check: latest, fetched 2026-09-06; receipt is not current; latest-session cause remains unassigned.
2026-09-28 stock-event scan:
research/stock-events/, no MDT row dated 2026-09-24 through 2026-09-28.2026-09-28 captured-follows scan: tweets has 0 September 24–28 document(s) tagging MDT.
Retrospective social-search receipt (captured 2026-09-29): 2026-09-29-social-search-mdt; quality/attention check only, not a September 28 event or price source.
2026-09-29 browser discovery check for MDT: news-discovery-google-sep29 (key
MDT); search links only, not evidence of an event or of absence of news.